Cisterna magna cannulated repeated CSF sampling rat model - effects of a gamma-secretase inhibitor on Aβ levels

Journal of Neuroscience Methods

Volumn 205, Issue 1, 2012, Pages 36-44

  Shapiro, Jennifer S ^a   Stiteler, Mark ^a   Wu, Guoxin ^a   Price, Eric A ^a   Simon, Adam J ^a,b   Sankaranarayanan, Sethu ^a,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Bristol Myers Squibb ^*  (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Abeta; Alzheimer's; Amyloid beta; Cerebrospinal fluid; Cisterna magna cannulation; Gamma secretase; Repeated CSF sampling

Indexed keywords

AMYLOID BETA PROTEIN; GAMMA SECRETASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CANNULA; CANNULATION; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CISTERNA MAGNA; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; RAT; SURGICAL TECHNIQUE;

EID: 84855877071     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2011.12.010     Document Type: Article

References (49)

1. Abramowski D., Wiederhold K.H., Furrer U., Jaton A.L., Neuenschwander A., Runser M.J., et al. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther 2008, 327:411-424.
2. Barten D.M., Guss V.L., Corsa J.A., Loo A., Hansel S.B., Zheng M., et al. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther 2005, 312:635-643.
3. Bateman R.J., Wen G., Morris J.C., Holtzman D.M. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007, 68:666-669.
4. Bateman R.J., Siemers E.R., Mawuenyega K.G., Wen G., Browning K.R., Sigurdson W.C., et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 2009, 66:48-54.
5. Best J.D., Jay M.T., Otu F., Ma J., Nadin A., Ellis S., et al. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-d ihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]. J Pharmacol Exp Ther 2005, 313:902-908.
6. Cassar S.C., Tovcimak A.E., Rustay N.R., Ellis T.A., Hooker B.A., Witte D.G., et al. Comparing levels of biochemical markers in CSF from cannulated and non-cannulated rats. J Neurosci Methods 2010, 192:249-253.
7. Cirrito J.R., May P.C., O'Dell M.A., Taylor J.W., Parsadanian M., Cramer J.W., et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 2003, 23:8844-8853.
8. Consiglio A.R., Lucion A.B. Technique for collecting cerebrospinal fluid in the cisterna magna of non-anesthetized rats. Brain Res Brain Res Protoc 2000, 5:109-114.
9. Cook J.J., Wildsmith K.R., Gilberto D.B., Holahan M.A., Kinney G.G., Mathers P.D., et al. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J Neurosci 2010, 30:6743-6750.
10. Davson H., Welch K., Segal M.B. Physiology and pathophysiology of the cerebrospinal fluid 1987, Churchill Livingstone, London, pp. 189-246.
11. El Mouedden M., Vandermeeren M., Meert T., Mercken M. Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for Abeta production inhibitors. Curr Pharm Des 2006, 12:671-676.
12. Fagan A.M., Holtzman D.M. Cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med 2010, 4:51-63.
13. Gillman K.W., Starrett J.E., Parker M.F., Xie K., Bronson J.J., Marcin L.R., et al. Evaluation of BMS-708163, a potent, selective and orally bioavailable (-secretase inhibitor. ACS Med Chem Lett 2010, 1:120-124.
14. Hampel H., Frank R., Broich K., Teipel S.J., Katz R.G., Hardy J., et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010, 9:560-574.
15. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006, 5:228-234.
16. Hu W.T., Chen-Plotkin A., Arnold S.E., Grossman M., Clark C.M., Shaw L.M., et al. Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease. Acta Neuropathol 2010, 120:385-399.
17. Huang Y.L., Säljö A., Suneson A., Hansson H.A. Comparison among different approaches for sampling cerebrospinal fluid in rats. Brain Res Bull 1996, 273-279.
18. Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, Ju YE, Kasten T, Morris JC, Mintun M, Duntley S, Bateman RJ. Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system. Arch Neurol., in press. doi:10.1001/archneurol.2011.235.
19. Hutson P.H., Sarna G.S., Kantamaneni B.D., Curzon G. Concurrent determination of brain dopamine and 5-hydroxytryptamine turnovers in individual freely moving rats using repeated sampling of cerebrospinal fluid. J Neurochem 1984, 43:151-159.
20. Hutson P.H., Sarna G.S., Kantamaneni B.D., Curzon G. Monitoring the effect of a tryptophan load on brain indole metabolism in freely moving rats by simultaneous cerebrospinal fluid sampling and brain dialysis. J Neurochem 1985, 44:1266-1273.
21. Ida N., Hartmann T., Pantel J., Schröder J., Zerfass R., Förstl H., et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 1996, 271:22908-22914.
22. Kandiah P., Ortega S., Torbey M.T. Biomarkers and neuroimaging of brain injury after cardiac arrest. Semin Neurol 2006, 26:413-421.
23. Kang J.E., Lim M.M., Bateman R.J., Lee J.J., Smyth L.P., Cirrito J.R., et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009, 326:1005-1007.
24. Lanz T.A., Hosley J.D., Adams W.J., Merchant K.M. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). J Pharmacol Exp Ther 2004, 309:49-55.
25. Lanz T.A., Karmilowicz M.J., Wood K.M., Pozdnyakov N., Du P., Piotrowski M.A., et al. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139. J Pharmacol Exp Ther 2006, 319:924-933.
26. Lanz T.A., Wood K.M., Richter K.E., Nolan C.E., Becker S.L., Pozdnyakov N., et al. Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014. J Pharmacol Exp Ther 2010, 334:269-277.
27. Li J, Llano DA, Ellis T, Leblond D, Bhathena A, Jhee SS, Ereshefsky L, Lenz R, Waring JF. Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels. Alzheimers Dement, in press. doi:10.1016/j.jalz.2011.05.900.
28. Lin J.H. CSF as a surrogate for assessing CNS exposure: an industrial perspective. Curr Drug Metab 2008, 9:46-59.
29. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. J Am Med Assoc 2009, 302:385-393.
30. Maurer M.H. Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF). Mass Spectrom Rev 2010, 29:17-28.
31. Nirogi R., Kandikere V., Mudigonda K., Bhyrapuneni G., Muddana N., Saralaya R., et al. A simple and rapid method to collect the cerebrospinal fluid of rats and its application for the assessment of drug penetration into the central nervous system. J Neurosci Methods 2010, 178:116-119.
32. Patsalos P.N., Alavijeh M.S., Semba J., Lolin Y.I. A freely moving and behaving rat model for the chronic and simultaneous study of drug pharmacokinetics (blood) and neuropharmacokinetics (cerebrospinal fluid): hematological and biochemical characterization and kinetic evaluation using carbamazepine. J Pharmacol Toxicol Methods 1992, 28:21-28.
33. Paweletz C.P., Wiener M.C., Bondarenko A.Y., Yates N.A., Song Q., Liaw A., et al. Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometry. J Proteome Res 2010, 9:1392-1401.
34. Pegg C.C., He C., Stroink A.R., Kattner K.A., Wang C.X. Technique for collection of cerebrospinal fluid from the cisterna magna in rat. J Neurosci Methods 2010, 187:8-12.
35. Petzold A. CSF biomarkers for improved prognostic accuracy in acute CNS disease. Neurol Res 2007, 29:691-708.
36. Portelius E., Van Broeck B., Andreasson U., Gustavsson M.K., Mercken M., Zetterberg H., et al. Acute effect on the Aβ isoform pattern in CSF in response to (-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis 2010, 21:1005-1012.
37. Riou E.M., Amlie-Lefond C., Echenne B., Farmer M., Sébire G. Cerebrospinal fluid analysis in the diagnosis and treatment of arterial ischemic stroke. Pediatr Neurol 2008, 38:1-9.
38. Rudick R.A., Zirretta D.K., Herndon R.M. Clearance of albumin from mouse subarachnoid space: a measure of CSF bulk flow. J Neurosci Methods 1982, 6:253-259.
39. Sankaranarayanan S., Price E.A., Wu G., Crouthamel M.C., Shi X.P., Tugusheva K., et al. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1. J Pharmacol Exp Ther 2008, 324:957-969.
40. Sankaranarayanan S., Holahan M.A., Colussi D., Crouthamel M.C., Devanarayan V., Ellis J., et al. First demonstration of cerebrospinal fluid and plasma Aβ lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther 2009, 328:131-140.
41. Sarna G.S., Hutson P.H., Tricklebank M.D., Curzon G. Determination of brain 5-hydroxytryptamine turnover in freely moving rats using repeated sampling of cerebrovascular fluid. J Neurochem 1983, 40:383-388.
42. Scott J.P., Oliver S.F., Brands K.M., Brewer S.E., Davies A.J., Gibb A.D., et al. Practical asymmetric synthesis of a gamma-secretase inhibitor exploiting substrate-controlled intramolecular nitrile oxide-olefin cycloaddition. J Org Chem 2006, 71:3086-3092.
43. Shen D.D., Artru A.A., Adkison K.K. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 2004, 56:1825-1857.
44. Siemers E.R., Quinn J.F., Kaye J., Farlow M.R., Porsteinsson A., Tariot P., et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006, 66:602-604.
45. Siemers E.R., Friedrich S., Dean R.A., Gonzales C.R., Farlow M.R., Paul S.M., et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010, 33:67-73.
46. Takasugi Y., Shirai T., Futagawa K., Koga Y., Egawa K., Watanabe S., et al. Transcutaneous cisternal puncture for sampling of cerebrospinal fluid in awake rat. Exp Anim 2005, 54:193-196.
47. Trojanowski J.Q., Vandeerstichele H., Korecka M., Clark C.M., Aisen P.S., Petersen R.C., et al. Alzheimer's disease neuroimaging initiative. Update on the biomarker core of the Alzheimer's disease neuroimaging initiative subjects. Alzheimers Dement 2010, 6:230-238.
48. van Dijk K.D., Teunissen C.E., Drukarch B., Jimenez C.R., Groenewegen H.J., Berendse H.W., et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol Dis 2010, 39:229-241.
49. Zheng H., Jiang M., Trumbauer M.E., Sirinathsinghji D.J., Hopkins R., Smith D.W., et al. Ploeg LH beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 1995, 81:525-531.